Status: Planned
First registered on:
26/06/2019
Last updated on:
05/10/2021
1. Study identification
EU PAS Register NumberEUPAS30280
Official titleThe BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
Study title acronymBRAHMS
Study typeObservational study
Brief description of the study
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupOdense University Pharrnacoepidemiological Database
Organisation/affiliationUniversity of Southern Denmark
Details of (Primary) lead investigator
Title Professor
Last name Hallas
First name Jesper
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?8
Countries in which this study is being conducted
International study
Denmark
Germany
Italy
Netherlands
Norway
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed17/04/2018
Start date of data collection01/01/2020
Start date of data analysis
Date of interim report, if expected
Date of final study report30/09/2030
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesLEO Pharma100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Hallas
First name Jesper
Address line 1JB Winsløwsvej 19,2
Address line 2
Address line 3
CityOdense C
PostcodeDK-5000
CountryDenmark
Phone number (incl. country code)45-65503010
Alternative phone number45-60191182
Fax number (incl. country code)45-65916089
Public Enquiries
Title Professor
Last name Hallas
First name Jesper
Address line 1JB Winsløwsvej 19,2
Address line 2
Address line 3
CityOdense C
PostcodeDK-5000
CountryDenmark
Phone number (incl. country code)45-65503010
Alternative phone number45-60191182
Fax number (incl. country code)45-65916089
6. Study drug(s) information
Substance class (ATC Code)L04AC12 (brodalumab)
7. Medical conditions to be studied
Medical condition(s)Yes
Psoriasis
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects50000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Danish National Health Databases, Denmark
Swedish National Health Database, Sweden
Norwegian National Health Databases, Norway
Sources of data
Administrative database, e.g. claims database
Exposure registry
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
The study aims to evaluate potential excess risks associated with the use of brodalumab in the treatment of psoriasis with regards to: 1) Suicidal attempts (fatal or non-fatal), 2) Serious infections (incident serious chronic infections or serious infections leading to hospitalization), 3) MACE (acute myocardial infarction, stroke or cardiovascular death), 4) Malignancies
Are there primary outcomes?Yes
1) Suicidal attempts (fatal or non-fatal), 2) Serious infections (incident serious chronic infections or serious infections leading to hospitalization), 3) MACE (acute myocardial infarction, stroke or cardiovascular death), 4) Malignancies
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
Case-crossover
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Two different designs are used:
A case-time-control design is used in the analysis of 1) serious infections 2) suicidal behaviour and 3) MACE. In this design a patient´s risk of experiencing an outcome while being exposed to brodalumab is compared to the same patient´s risk of an outcome while not being exposed. Due to the inherently matched nature of the case-time-control design conditional logistic regression is used to calculate odds ratios. An active-comparator cohort design is used in the analysis of 1) serious infections, 2) suicidal behaviour, 3) MACE, and 4) malignancies. In this design, the event rate of outcomes among subjects exposed to brodalumab is compared to the event rate of outcomes among subjects who are exposed to other biological drugs. In the cohort design propensity score matching is used to adjust for confounding, whereas Cox proportional hazard model is used to calculate hazard ratios.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
Yes
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Other documents
DescriptionDocumentLatest version
